These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27002921)

  • 1. Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.
    Cassaday RD; Alan Potts D; Stevenson PA; Bar M; Georges GE; Shustov AR; Sorror ML; Wood BL; Delaney C; Doney KC; Storb RF; Sandmaier BM
    Leuk Lymphoma; 2016 Sep; 57(9):2109-18. PubMed ID: 27002921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.
    Bachanova V; Marks DI; Zhang MJ; Wang H; de Lima M; Aljurf MD; Arellano M; Artz AS; Bacher U; Cahn JY; Chen YB; Copelan EA; Drobyski WR; Gale RP; Greer JP; Gupta V; Hale GA; Kebriaei P; Lazarus HM; Lewis ID; Lewis VA; Liesveld JL; Litzow MR; Loren AW; Miller AM; Norkin M; Oran B; Pidala J; Rowe JM; Savani BN; Saber W; Vij R; Waller EK; Wiernik PH; Weisdorf DJ
    Leukemia; 2014 Mar; 28(3):658-65. PubMed ID: 23989431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
    Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
    PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.
    Yoon JH; Min GJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
    Cancer; 2019 Mar; 125(6):873-883. PubMed ID: 30521062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2.
    Nishiwaki S; Akahoshi Y; Mizuta S; Shinohara A; Hirabayashi S; Noguchi Y; Fukuda T; Uchida N; Tanaka M; Onizuka M; Ozawa Y; Ota S; Shiratori S; Onishi Y; Kanda Y; Sawa M; Tanaka J; Atsuta Y; Kako S
    Blood Adv; 2021 Jan; 5(2):584-592. PubMed ID: 33496752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
    Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
    J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
    Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
    Walter RB; Buckley SA; Pagel JM; Wood BL; Storer BE; Sandmaier BM; Fang M; Gyurkocza B; Delaney C; Radich JP; Estey EH; Appelbaum FR
    Blood; 2013 Sep; 122(10):1813-21. PubMed ID: 23847197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.
    Bourlon C; Lacayo-Leñero D; Inclán-Alarcón SI; Demichelis-Gómez R
    Curr Oncol Rep; 2018 Mar; 20(4):36. PubMed ID: 29577208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yoon JH; Yhim HY; Kwak JY; Ahn JS; Yang DH; Lee JJ; Kim SJ; Kim JS; Park SJ; Choi CW; Eom HS; Park SK; Choi SY; Kim SH; Kim DW; Lee S
    Ann Oncol; 2016 Jun; 27(6):1081-1088. PubMed ID: 26951627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
    Nagafuji K; Miyamoto T; Eto T; Kamimura T; Taniguchi S; Okamura T; Ohtsuka E; Yoshida T; Higuchi M; Yoshimoto G; Fujisaki T; Abe Y; Takamatsu Y; Yokota S; Akashi K; Harada M
    J Hematol Oncol; 2013 Feb; 6():14. PubMed ID: 23388549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
    Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.
    Gilleece MH; Shimoni A; Labopin M; Robinson S; Beelen D; Socié G; Unal A; Ganser A; Vitek A; Sengeloev H; Yakoub-Agha I; Tholouli E; Polge E; Mohty M; Nagler A
    Blood Cancer J; 2021 May; 11(5):88. PubMed ID: 33980810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT.
    Akahoshi Y; Nishiwaki S; Arai Y; Harada K; Najima Y; Kanda Y; Shono K; Ota S; Fukuda T; Uchida N; Shiratori S; Tanaka M; Tanaka J; Atsuta Y; Kako S
    Bone Marrow Transplant; 2020 Jul; 55(7):1317-1325. PubMed ID: 32447350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China.
    Ding Z; Han MZ; Chen SL; Ma QL; Wei JL; Pang AM; Zhang XY; Liang C; Yao JF; Cao YG; Feng SZ; Jiang EL
    Chin Med J (Engl); 2015 Aug; 128(15):2065-71. PubMed ID: 26228220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.
    Tucunduva L; Ruggeri A; Sanz G; Furst S; Cornelissen J; Linkesch W; Mannone L; Ribera JM; Veelken H; Yakoub-Agha I; González Valentín ME; Schots R; Arcese W; Montesinos P; Labopin M; Gluckman E; Mohty M; Rocha V
    Br J Haematol; 2014 Sep; 166(5):749-57. PubMed ID: 24961645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.
    Cassaday RD; Stevenson PA; Wood BL; Becker PS; Hendrie PC; Sandmaier BM; Radich JL; Shustov AR
    Am J Hematol; 2018 Aug; 93(4):546-552. PubMed ID: 29318644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
    Araki D; Wood BL; Othus M; Radich JP; Halpern AB; Zhou Y; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
    J Clin Oncol; 2016 Feb; 34(4):329-36. PubMed ID: 26668349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.